CRISPR Therapeutics AG (NASDAQ: CRSP) had its price target raised by analysts at Morgan Stanley from $30.00 to $32.00. They now have an "underweight" rating on the stock.
MediumReport
CRISPR Therapeutics AG (NASDAQ: CRSP) had its price target raised by analysts at Morgan Stanley from $30.00 to $32.00. They now have an "underweight" rating on the stock.
CRISPR Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $99.00 price target on the stock, up previously from $60.00.
MediumReport
CRISPR Therapeutics AG (NASDAQ: CRSP) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $99.00 price target on the stock, up previously from $60.00.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: